Prelude Therapeutics (PRLD) Non-cash Items (2020 - 2026)

Prelude Therapeutics has disclosed Non-cash Items across 7 years of filings, most recently posting $10.1 million for Q1 2026.

• Non-cash Items for Q1 2026 came in at $10.1 million, up 14.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.1 million (up 14.5% YoY), and the FY2025 annual result was $7.5 million, up 7400.0% from the prior year.
• Non-cash Items came in at $10.1 million for Q1 2026 at Prelude Therapeutics, up from $7.5 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $12.1 million in Q3 2022 to a low of $100000.0 in Q4 2024.
• The 5-year median for Non-cash Items is $6.4 million (2024), against an average of $6.6 million.
• Across the five-year window, Non-cash Items sank 98.36% in 2024 and soared 7400.0% in 2025, its largest moves.
• Prelude Therapeutics' Non-cash Items stood at $3.6 million in 2022, then soared by 69.31% to $6.1 million in 2023, then tumbled by 98.36% to $100000.0 in 2024, then jumped by 7400.0% to $7.5 million in 2025, then jumped by 34.69% to $10.1 million in 2026.
• The last three Non-cash Items figures came in at $10.1 million (Q1 2026), $7.5 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.